
recurrence, but more standardization is required.
Primary Prevention. Cost-effectiveness of VLU prevention is difÔ¨Åcult to rigorously prove owing to the
requirement for large patient numbers in these trials and
the heterogeneous nature of CVI. Adequate compression
in a compliant patient with C1-C4 disease and the use of
evidence-based therapies for treatment with prevention of
DVT recurrence should go a long way toward decreasing
the incidence of VLU. Although much information